Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238467 · ClinicalTrials.gov registry record
Immunological Responses of COVID-19 Vaccination
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT05238467: Completed study, sponsored by University Hospitals Cleveland Medical Center.
NCT05238467 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05238467 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Cancer patients with COVID-19 have a 30% higher mortality rate compared to the general population and are considered a high-risk group by the American Association for Cancer Research that should be given "high priority" during COVID-19 vaccine administration. Although studies have suggested that vaccination during active treatment with chemo and/or radiation therapy provides suboptimal antibody response, the studies were underpowered and heterogeneous thus putting this conclusion into question. We need data in cancer patients on immunosuppressive chemotherapy at the time of COVID vaccination to understand how immune responses compare to healthy controls and cancer patients not on immunosuppressive therapy.
Primary Outcome
had an antibody titer protective (1:40) at any point in testing
Interventions
- OTHER COVID antibody titers in the blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2023-02-13 |
What the finished NCT05238467 record still lists
NCT05238467 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which COVID antibody titers in the blood is the first listed.
NCT05238467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05238467 about?
NCT05238467 is a clinical study titled "Immunological Responses of COVID-19 Vaccination". Cancer patients with COVID-19 have a 30% higher mortality rate compared to the general population and are considered a high-risk group by the American Association for Cancer Research that should be given "high priority" during COVID-19 vaccine administration. Although studies have suggested that vac...
What is the current status of trial NCT05238467?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2021-05-21. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT05238467?
The interventions under investigation include: COVID antibody titers in the blood (OTHER).
Who is sponsoring clinical trial NCT05238467?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI